Astellas Wins Patent Ruling Blocking Ascent’s Myrbetriq Copies

Copies of Astellas Pharma Inc.‘s Myrbetriq ER proposed by Ascent Pharmaceuticals Inc. infringe four patents for the overactive-bladder drug, a federal judge ruled, delaying their launch until 2030.

Ascent’s generic tablets of mirabegron, the drug’s active ingredient, infringe US Patent Nos. 10,842,780, 11,707,451, 12,059,409 and 12,097,189, according to Judge Joseph F. Bataillon’s opinion docketed Monday in the US District Court for the District of Delaware.

Bataillon, a senior judge sitting by designation from the District of Nebraska, also found the patents cover specific manmade drug compositions and treatment methods. He rejected Ascent’s arguments that they claim ...